These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 20410767)
1. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Meyer LA; Anderson ME; Lacour RA; Suri A; Daniels MS; Urbauer DL; Nogueras-Gonzalez GM; Schmeler KM; Gershenson DM; Lu KH Obstet Gynecol; 2010 May; 115(5):945-952. PubMed ID: 20410767 [TBL] [Abstract][Full Text] [Related]
2. Uptake of testing for germline Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686 [TBL] [Abstract][Full Text] [Related]
3. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961 [TBL] [Abstract][Full Text] [Related]
4. Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study. Armstrong J; Toscano M; Kotchko N; Friedman S; Schwartz MD; Virgo KS; Lynch K; Andrews JE; Aguado Loi CX; Bauer JE; Casares C; Bourquardez Clark E; Kondoff MR; Molina AD; Abdollahian M; Walker G; Sutphen R JAMA Oncol; 2015 Dec; 1(9):1251-60. PubMed ID: 26426480 [TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991 [TBL] [Abstract][Full Text] [Related]
6. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903 [TBL] [Abstract][Full Text] [Related]
7. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535 [TBL] [Abstract][Full Text] [Related]
8. Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system. Bellcross CA; Peipins LA; McCarty FA; Rodriguez JL; Hawkins NA; Hensley Alford S; Leadbetter S Genet Med; 2015 Jan; 17(1):43-50. PubMed ID: 24946155 [TBL] [Abstract][Full Text] [Related]
9. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing. Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053 [TBL] [Abstract][Full Text] [Related]
10. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic. Riedlova P; Janoutova J; Hermanova B Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084 [TBL] [Abstract][Full Text] [Related]
11. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254 [TBL] [Abstract][Full Text] [Related]
12. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. Hoskins PJ; Gotlieb WH CA Cancer J Clin; 2017 Nov; 67(6):493-506. PubMed ID: 28881380 [TBL] [Abstract][Full Text] [Related]
13. Recruiting African American women to participate in hereditary breast cancer research. Halbert CH; Brewster K; Collier A; Smith C; Kessler L; Weathers B; Stopfer JE; Domchek S; Wileyto EP J Clin Oncol; 2005 Nov; 23(31):7967-73. PubMed ID: 16258097 [TBL] [Abstract][Full Text] [Related]
14. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Herman J Obstet Gynecol; 2010 Aug; 116(2 Pt 1):440-441. PubMed ID: 20664408 [No Abstract] [Full Text] [Related]
15. Keeping it simple: genetics referrals for all invasive serous ovarian cancers. Demsky R; McCuaig J; Maganti M; Murphy KJ; Rosen B; Armel SR Gynecol Oncol; 2013 Aug; 130(2):329-33. PubMed ID: 23707676 [TBL] [Abstract][Full Text] [Related]
16. Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling? Powell CB; Littell R; Hoodfar E; Sinclair F; Pressman A Int J Gynecol Cancer; 2013 Mar; 23(3):431-6. PubMed ID: 23354368 [TBL] [Abstract][Full Text] [Related]
17. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Nelson HD; Pappas M; Cantor A; Haney E; Holmes R JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902 [TBL] [Abstract][Full Text] [Related]
18. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Moyer VA; Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376 [TBL] [Abstract][Full Text] [Related]
19. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246 [TBL] [Abstract][Full Text] [Related]
20. Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals. Stuckey A; Febbraro T; Laprise J; Wilbur JS; Lopes V; Robison K Am J Clin Oncol; 2016 Aug; 39(4):363-7. PubMed ID: 24710121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]